DailyIQ
Last updated1 minute ago

UNH·UnitedHealth Group Incorporated

$393.68
+15.92 (+4.21%)
High
$395.50
Open
$382.29
Market Cap
337.65B
52W High
$461.62
Low
$377.62
P. Close
$393.68
P/E
23.91
52W Low
$255.96
Fwd P/E
16.92
DailyIQ Est.
$495.00
Inst. Ownership
44.3%
Short Interest
1.79%
Days to Cover
3.3
Div. Yield
2.40%
Next Ex-Div
~Dec 14
Div. Growth
15+ yrs
NewEarnings release, scored · filed Oct 13, 2026Guidance raised · tone +2.6 vs prior release · 127 lines scoredSee the breakdown
Technical Score (1D)
47
NEUTRAL
News Sentiment
65
BULLISH
On Oct 13, UnitedHealth Group reported Q3 2026 revenue of $112.7 billion, slightly below the prior year but with adjusted earnings per share rising to $4.69 from $2.92, a gain that beat consensus estimates. The medical cost ratio improved to 88.4 percent, attributed to AI‑enabled administrative efficiencies and benefit redesign, and the operating cost ratio fell to 12.8 percent from 13.5 percent, reflecting realized efficiencies and modernization investments. UnitedHealth reiterated its full‑year 2026 guidance of at least $20.50 in adjusted earnings per share, indicating confidence in continued performance. Despite the upgraded outlook, the stock slipped 0.7 percent to $375.86 on Oct 13, reflecting investor caution about sustaining the earnings recovery. The company’s ability to maintain pricing and benefit design will be critical to support the upgraded outlook.
LOW TARGET
$380 -3.5%
1 analysts
MEAN TARGET
$481 +22.1%
21 analysts
HIGH TARGET
$529 +34.4%
14 analysts
PRICE RANGE
$380.00 - $529.00
SB / B / H / S / SS
8/19/7/1/1
DAILYIQ EST.
$495.00 (+25.7%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Symbol
UNH
Description
UnitedHealth Group is a diversified healthcare enterprise providing a broad range of services across the U.S. and internationally. The company's core value proposition revolves around its integrated structure, encompassing four primary segments. UnitedHealthcare focuses on providing health benefit plans and related services to a diverse customer base, including employers, individuals, and government programs. Optum Health delivers care delivery, management, and financial services to various healthcare stakeholders. Optum Insight provides data analytics, software solutions, and consulting services to healthcare providers and payers. Finally, Optum Rx offers pharmacy care services and programs, including prescription fulfillment and clinical management. This multifaceted approach allows UnitedHealth Group to serve a wide spectrum of healthcare needs.
Bought (1Y)
0 shares
$0
Sold (1Y)
4,135.999 shares
$1.6M
Baker Charles D.-
Award/Grant257 shares2026-10-01
FLYNN TIMOTHY PATRICK-
Award/Grant262 shares2026-10-01
GARCIA PAUL R-
Award/Grant103 shares2026-10-01
GARCIA PAUL R-
Award/Grant155 shares2026-10-01
Gil Kristen-
Award/Grant240 shares2026-10-01
69/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
2.7%
Revenue CAGR
10.4%
Current Ratio
0.79x
Debt / Equity
0.78x
Return on Equity
12.0%
Earnings Summary
UnitedHealth Group is a diversified healthcare enterprise offering health benefit plans, care delivery, data analytics, and pharmacy services across the U.S. and internationally, positioning it as a leading player in the healthcare plans sector. In the most recent quarter, Q3 2026, the company generated $112.7 billion in revenue, a slight decline from the prior year, while adjusted earnings per share rose to $4.69 from $2.92, beating consensus estimates; this contrasts with Q4 2025 where revenue of $113.2 billion exceeded the estimate but EPS of $2.11 fell short of the $2.12 forecast. The company’s EPS trend shows a rebound in Q2 2026, where actual EPS of $6.38 surpassed the $3.74 estimate, and a modest increase in Q3 2026, indicating a recent acceleration in earnings growth despite revenue softness. UnitedHealth has consistently beat earnings estimates in three of the last four quarters, though revenue has occasionally missed forecasts, reflecting a pattern of strong profitability amid modest revenue volatility. Historically, the firm has maintained year-over-year revenue growth, with notable EPS beats in Q1 2025 and Q3 2026, while occasionally missing revenue targets, suggesting a resilient earnings engine. Recent news highlights the company’s improved medical cost ratio to 88.4 percent and lower operating cost ratio, attributed to AI-enabled efficiencies and benefit redesign, which underpin the upgraded 2026 adjusted earnings outlook of at least $20.50 per share; however, investor caution remains due to concerns about sustaining the earnings recovery.

EPS

EstBeatMiss
$1.34$3.01$4.67$6.33$8.00Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$4.19$4.69+12.0%
Q2'26$3.74$6.38+70.4%
Q1'26$6.60$7.23+9.5%
Q4'25$2.12$2.11-0.6%
Q3'25$2.81$2.92+4.0%

Revenue

EstBeatMiss
$108.9B$110.6B$112.3B$114.0B$115.8BQ3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$112.5B$112.7B+0.2%
Q2'26$111.9B$112.0B+0.1%
Q1'26$109.7B$111.7B+1.9%
Q4'25$115.0B$113.2B-1.5%
Q3'25 - $113.2B -

Market Data

UNH Stock Snapshot

NEUTRAL47/100
$393.68+$15.92 (4.2%)
Market cap
337.65B
P/E ratio
23.9
Day range
$377.62 – $395.50
News sentiment
65/100 · Bullish
Analyst target
$480.60 (+22.1%)
Consensus
Buy · 36 analysts
52-week range+53.8% off low · -14.7% from high
$255.96$461.62
Price $393.68 DailyIQ Est. $495.00

The setup on UnitedHealth Group Incorporated is patient: consolidation, not accumulation or distribution. Positioning shifts among large allocators, not retail flow, set the tone for a name this size.

Reverse DCF

What growth is priced into UNH?

FAIR

At today's price, UnitedHealth Group Incorporated needs to grow free cash flow about 8.6% a year for the next 10 years to justify its valuation at a 7.85% cost of capital. Over its actual history it has compounded free cash flow at 11.3% a year, so the market is asking for 2.7 percentage points below its own delivered rate. On that basis UNH looks priced roughly in line with its own growth record.

Implied FCF growth
8.6%
Historical FCF CAGR
11.3%
Growth gap
-2.7 pts
Verdict
FAIR
Discount rate (WACC)
7.85%
Beta
0.68

Behaviour On Record

What UNH's own history says about today's numbers

Realized volatility (21d)
17.3% 26th pct
Below its peak
-39.5%
vs 200-day average
+6.0%
Up days (1y)
47%

UnitedHealth Group Incorporated is currently running 17.3% annualised volatility over the last 21 sessions. Measured against UNH's own 13 years of daily returns rather than a market-wide average, that is the 26th percentile — on the quiet side for this stock, against a typical reading of 22.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

UNH is trading -39.5% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -16.0%, and the deepest was -60.6% in 2025. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +6.0% from its 200-day moving average. Against every other day in its history, that gap ranks at the 41st percentile — close to the gap it normally carries. Over the past year UNH closed higher on 47% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 14 years of records, UNH finished the month higher 9 of 14 times, with a median return of +2.8% and an average of +3.7%. Its strongest month historically has been November at +5.1% on average, its weakest February at -1.2%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: UNH has opened more than 2% away from the prior close in 41 of 3,268 sessions (1.3% of the time), with the largest gaps running +9.3% and -6.4%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 4 dated reports on file, UNH moved an average of 1.4% in the session after earnings, closing higher 4 of those 4 times, with a median move of +1.3% and a largest of +3.2%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against UNH's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of UNH's sector?

UnitedHealth Group Incorporated sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#2 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for UNH?

CallsPuts

For UnitedHealth Group Incorporated's nearest expiry (2026-10-16, 2 days out), open interest is roughly balanced between puts and calls (put/call ratio of 1.00), with at-the-money implied volatility around 28.7%. The options market is pricing roughly a ±2.5% move by that expiry — a range of about $381.56–$401.32.

Put/call ratio (2026-10-16)
1.00
ATM implied volatility
28.7%
Total open interest
105,744
Expected move by 2026-10-16
±2.5% ($381.56–$401.32)

Analyst Rating Changes

Are analysts turning bullish or bearish on UNH?

TD Cowen most recently reiterated its rating on UnitedHealth Group Incorporated to Hold on Oct 9, 2026 with a price target of $402 (from $430). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
TD Cowen — Hold
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 9, 2026TD CowenMaintainedHold$430 → $402
Jul 21, 2026JP MorganMaintainedOverweight$466 → $516
Jul 21, 2026MizuhoMaintainedOutperform$470 → $493
Jul 20, 2026BarclaysMaintainedOverweight$429 → $441
Jul 17, 2026Morgan StanleyMaintainedOverweight$468 → $529
Jul 17, 2026KeybancMaintainedOverweight$475 → $500
Jul 17, 2026OppenheimerMaintainedOutperform$420 → $500
Jul 17, 2026Truist SecuritiesMaintainedBuy$480 → $500
Jul 17, 2026RBC CapitalMaintainedOutperform$463 → $478
Jul 17, 2026UBSMaintainedBuy$460 → $490
Jul 16, 2026BairdUpgradeUnderperform → Neutral$287 → $453
Jul 14, 2026TD CowenMaintainedHold$337 → $430

Earnings Release, Scored

What did UnitedHealth Group Incorporated's latest earnings release say?

Filed Oct 13, 2026 · SEC Form 8-K, Exhibit 99

Guidance raised
Tone58.8/ 100+2.6 vs prior release
Hedging words0.22per 100 words+0.09 vs prior release
Tone, last 2 releasesScale 50–70

Most important lines

  1. 1

    1 UnitedHealth Group Reports Third Quarter 2026 Results • Third Quarter 2026 Revenues of $112.7 Billion; Earnings from Operations of $6.6 Billion • Earnings of $4.56 Per Share and Adjusted Earnings of $4.69 Per Share • Cash Flows from Operations Were $5.1 Billion, or 1.2x Net Income • Updated Full Year 2026 Earnings Outlook to At Least $19.50 Per Share; Adjusted Earnings of At Least $20.50 Per Share To view this information in a different format, including graphics, published on our website, click here: https://www.unitedhealthgroup.com/content/dam/UHG/PDF/investors/2026/unh-reports-third-quarter-2026-results.pdf (October 13, 2026) UnitedHealth Group (NYSE: UNH) today reported third quarter 2026 results and raised guidance for full year 2026.

    Guidance raised
  2. 2

    Optum Rx • Optum Rx continues to advance transparent pharmacy pricing while broadening the clinically integrated pharmacy services that patients depend on. • Optum Rx’s third quarter 2026 revenues were $39.9 billion compared to $39.7 billion in the third quarter 2025. • Earnings from operations for the third quarter 2026 were $1.7 billion compared to $1.5 billion in the third quarter 2025, reflecting continued adoption of biosimilars and operational improvements.

    New this quarter
  3. 3

    Quarterly Financial Performance Three Months Ended September 30, 2026 September 30, 2025 June 30, 2026 Revenues $66.9 billion $69.2 billion $65.7 billion Earnings from Operations $3.7 billion $2.5 billion $4.0 billion Operating Margin 5.6% 3.6% 6.2% Optum Health • Optum Health continues to progress in operational enhancements that expand patient access to integrated, quality care resources while modernizing the care experience to allow for greater patient satisfaction and a more engaged clinician experience. • Optum Health’s third quarter 2026 revenues of $22.9 billion decreased 10% year-over-year as a result of fewer value-based care patients served in markets where Optum lacked sufficient value-based care presence to sustain its clinicians. • Third quarter 2026 earnings from operations were $735 million and operating margin was 3.2%, compared to $41 million and 0.2% in the third quarter 2025.

    New this quarterNegative tone

Peers & ETF holders

UNH peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

65/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
UnitedHealth Group reported Q3 2026 revenue of $112.7 billion, exceeding analyst expectations, while adjusted EPS rose to $4.69, a 13.3% beat. Operating margin climbed to 5.8% from 3.8% a year earlier, reflecting successful cost‑control initiatives. Management highlighted AI‑driven efficiencies and disciplined benefit design, particularly in Medicare Advantage, as key contributors to the improved financial performance.
What did this article say?
UnitedHealth Group reported third‑quarter earnings that exceeded consensus estimates, with adjusted EPS beating by 13%. The medical loss ratio improved by 150 basis points, largely driven by favorable prior‑period adjustments. Mizuho Securities highlighted the continued durability of margin recovery across UnitedHealthcare and OptumHealth as a key driver of confidence in the insurer’s profitability trajectory.
What did this article say?
UnitedHealth reported Q3 2026 revenue of $112.7 billion, slightly below the prior year but with a notable rise in adjusted EPS to $4.69 from $2.92. The medical care ratio improved to 88.4%, driven by AI‑enabled administrative efficiencies and benefit design changes. Operating cost ratio fell to 12.8% from 13.5%, reflecting realized efficiencies and modernization investments. The company reiterated full‑year 2026 guidance of at least $20.50 in adjusted EPS, indicating confidence in continued performance.
What did this article say?
UnitedHealth Group reported Q3 earnings that surpassed estimates, with adjusted earnings of $4.69 per share versus the $4.12 consensus. Revenue reached $112.69 billion, slightly below the prior‑year quarter but above expectations. The medical cost ratio improved to 88.4% from 89.9%, indicating better cost control and a potential earnings rebound for the year.
What did this article say?
UnitedHealth Group increased its 2026 adjusted earnings outlook to at least $20.50 per share, citing stronger operating performance and a lower medical‑cost ratio. The company reported $112.7 billion in revenue, $6.6 billion in operating earnings and $4.69 per share in adjusted earnings for the quarter. Despite the optimistic guidance, the stock slipped 0.7% to $375.86, reflecting investor caution about sustaining the earnings recovery. The valuation gap remains wide, with shares trading roughly 18.3 times the minimum adjusted earnings forecast. The company’s ability to maintain pricing and benefit design will be critical to support the upgraded outlook.
What did this article say?
UnitedHealth (UNH) is set to report earnings on Tuesday, with analysts forecasting a 1.6% year‑over‑year revenue decline after a 12.2% increase last year. The company previously beat revenue and EPS estimates, but has missed Wall Street revenue targets multiple times in the past two years. Market sentiment remains cautious, as investors weigh the expected slowdown against the firm’s recent strong performance. The earnings release is likely to be closely watched for any guidance updates that could influence the stock’s trajectory.
What did this article say?
In early October 2026, UnitedHealthcare announced its 2027 Medicare Advantage lineup, featuring $0 primary and preventive care and an expanded focus on HMO, Dual Special Needs, and Chronic Special Needs plans. The redesign aims to streamline care coordination and benefit integration for members with complex medical and social needs while maintaining low out‑of‑pocket costs. Updates to the UCard program were also introduced to simplify access to benefits and medications for Medicare‑eligible members. The changes are expected to strengthen UnitedHealth’s competitive position in the Medicare market and support its long‑term growth narrative.
What did this article say?
UnitedHealth’s share of Medicare Advantage members in four‑star or higher plans fell to 67% for 2027, down from 81% in 2026, according to J.P. Morgan’s analysis. The downgrade signals a potential revenue hit as higher‑rated plans typically command better reimbursement rates. UnitedHealth confirmed the rating trend aligns with expectations but noted the industry average is improving, widening the gap. The decline may pressure the company’s earnings outlook and could prompt management to address member distribution in upcoming earnings calls.
What did this article say?
UnitedHealth Group closed at $378.81 on October 9, up 2.12% from the previous day, outperforming the S&P 500 and other major indices. The insurer’s stock had declined 4.46% over the past month, lagging the broader medical sector. Investors are watching the upcoming earnings announcement on October 13, with analysts forecasting EPS of $4.12 and revenue of $111.38 billion for the quarter, slightly below year‑ago levels. Full‑year guidance remains near $19.85 per share and $446.78 billion in revenue, indicating modest year‑over‑year growth.
What did this article say?
UnitedHealth Group Inc. (UNH) is confronting a mixed outlook as management seeks to restore profitability margins while maintaining flat revenue growth. The company’s cash flow remains robust, yet compressed margins and underperformance relative to the broader market raise concerns. Analysts note that the current forward P/E already assumes an earnings turnaround, but the path to achieving this remains uncertain. The focus on Florida WellMed clinics highlights a specific turnaround initiative, though its impact on overall topline expansion is unclear. Overall, the situation presents a cautious view of UNH’s near‑term performance.

Technical Analysis

Real-time indicators across multiple timeframes

47
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $150.28B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy76,863,0618.63%$31.95B2026-08-07
Vanguard Group Inc▲ Buy91,600,26010.28%$30.24B2026-01-29
Capital World Investors▲ Buy29,887,9323.35%$12.42B2026-08-12
FMR LLC (Fidelity)▲ Buy27,992,9953.14%$11.63B2026-08-13
Geode Capital Management, LLC▼ Sell21,751,9372.44%$9.01B2026-08-12
JPMorgan Chase & Co▲ Buy20,246,0472.27%$8.50B2026-08-12
Morgan Stanley▼ Sell14,795,4561.66%$6.15B2026-08-13
Norges Bank▼ Sell12,736,9731.43%$5.29B2026-08-12
Wellington Management Group LLP▲ Buy10,675,1751.20%$4.44B2026-08-14
Capital Research Global Investors▼ Sell10,534,1771.18%$4.38B2026-08-12
Bank of America Corp▼ Sell9,735,8741.09%$4.05B2026-08-14
Fisher Asset Management, LLC▲ Buy9,082,2691.02%$3.77B2026-08-04
Northern Trust Corp▼ Sell8,761,0550.98%$3.64B2026-08-13
Goldman Sachs Group Inc▼ Sell6,974,1320.78%$2.90B2026-08-14
Invesco Ltd.▲ Buy6,858,9840.77%$2.85B2026-08-14
AllianceBernstein L.P.▲ Buy7,669,4200.86%$2.08B2026-08-14
Wells Fargo & Company▲ Buy3,618,5790.41%$1.50B2026-08-14
Janus Henderson Group plc▲ Buy3,691,6070.41%$991.45M2026-05-18
Susquehanna International Group, LLP▼ Sell1,883,7670.21%$782.95M2026-08-14
Marshall Wace, LLP▲ Buy1,833,0460.21%$761.87M2026-08-13
AQR Capital Management LLC▲ Buy1,757,5500.20%$729.08M2026-08-14
Millennium Management LLC▲ Buy1,617,6530.18%$672.35M2026-08-14
Davis Selected Advisers▲ Buy1,274,6500.14%$529.84M2026-08-11
Farallon Capital Management LLC▼ Sell1,270,5320.14%$528.07M2026-08-14
Citigroup Inc▼ Sell1,173,0150.13%$487.54M2026-08-03
Q2 2026 flow:30.57M sh bought ($12.53B)13.34M sh sold ($5.54B)net +17.23M sh (+$6.99B)
Congressional Trading Activity
25 disclosed trades · ~$640.5K est. traded value · 10 buys, 15 sells
MemberChamberStateTypeAmountTradedFiled
Maria Elvira SalazarHouseFL27▼ Sell$1K - $15K2026-09-242026-10-07
Kevin HernHouseOK01▼ Sell$15K - $50K2026-09-102026-09-25
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2026-07-302026-08-14
Dan NewhouseHouseWA04▼ Sell$1K - $15K2026-07-102026-07-17
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2026-06-122026-07-09
Maria Elvira SalazarHouseFL27▼ Sell$1K - $15K2026-06-042026-07-07
John BoozmanSenateAR▲ Buy$1K - $15K2026-06-042026-07-13
Maria Elvira SalazarHouseFL27▲ Buy$1K - $15K2026-04-222026-05-08
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-04-142026-05-08
Alan ArmstrongSenateOK▲ Buy$15K - $50K2026-03-272026-07-21
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2026-03-192026-04-07
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2026-03-132026-04-07
Gilbert CisnerosHouseCA31▼ Sell$15K - $50K2026-02-102026-03-09
Josh GottheimerHouseNJ05▲ Buy$1K - $15K2026-02-052026-03-16
Kevin HernHouseOK01▼ Sell$250K - $500K2025-12-232026-01-22
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-12-182026-01-15
Julie JohnsonHouseTX32▼ Sell$1K - $15K2025-11-132025-12-11
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-11-122025-12-15
Richard Dean Dr McCormickHouseGA06▲ Buy$1K - $15K2025-11-052025-12-09
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-10-092025-11-18
Valerie HoyleHouseOR04▼ Sell$1K - $15K2025-09-232025-10-10
Richard Dean Dr McCormickHouseGA06▼ Sell$1K - $15K2025-09-182025-10-09